TY - JOUR
T1 - Stereotactic body radiotherapy in the treatment of adrenal metastases
AU - Ahmed, Kamran A.
AU - Barney, Brandon M.
AU - Macdonald, O. Kenneth
AU - Miller, Robert C.
AU - Garces, Yolanda I.
AU - Laack, Nadia N.
AU - Haddock, Michael G.
AU - Foote, Robert L.
AU - Olivier, Kenneth R.
PY - 2013/10
Y1 - 2013/10
N2 - OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3%) were evaluable for local control (LC). The crude LC rate was 100%, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9% and 55%, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.
AB - OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3%) were evaluable for local control (LC). The crude LC rate was 100%, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9% and 55%, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.
KW - Adrenal metastases
KW - Intensity-modulated radiotherapy
KW - Stereotactic body radiation therapy
KW - Stereotactic radiosurgery
UR - http://www.scopus.com/inward/record.url?scp=84885018340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885018340&partnerID=8YFLogxK
U2 - 10.1097/COC.0b013e3182569189
DO - 10.1097/COC.0b013e3182569189
M3 - Article
C2 - 22781389
AN - SCOPUS:84885018340
SN - 0277-3732
VL - 36
SP - 509
EP - 513
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 5
ER -